Online first
Artykuł przeglądowy
Opublikowany online: 2024-09-16
Wyświetlenia strony
359
Wyświetlenia/pobrania artykułu
82
Postępy w onkologii przewodu pokarmowego — podsumowanie roku 2023
1
, 2
, 2
Streszczenie
W ostatnich latach dokonuje się istotny postęp w terapii nowotworów przewodu pokarmowego, a rok 2023 kontynuował ten trend. W minionym roku zaprezentowano wyniki badań, które dotyczyły praktycznie każdego aspektu leczenia onkologicznego i każdego rodzaju rozpoznania. W przypadku wczesnych nowotworów jelita grubego, przełyku i trzustki dąży się do coraz bardziej spersonalizowanego podejścia do leczenia przedoperacyjnego, natomiast w zaawansowanych przypadkach raka jelita grubego pojawiają się nowe opcje późnoliniowej terapii paliatywnej. Znaczące zmiany zachodzą w obszarze immunoterapii, zwłaszcza w przypadku terapii chorych na raki przełyku, żołądka i wątroby. Dodatkowo, pojawia się szereg obiecujących perspektyw w dziedzinie leczenia ukierunkowanego molekularnie, w tym te dotyczące terapii chorych na nieresekcyjne raki żołądka, trzustki i dróg żółciowych. Dynamiczny rozwój onkologii wymusza na lekarzach-praktykach stałą aktualizację wiedzy.
Celem niniejszego artykułu jest przedstawienie subiektywnego przeglądu postępów w dziedzinie onkologii przewodu pokarmowego w roku 2023, z uwzględnieniem kontekstu badań i potencjału do zmiany praktyki klinicznej.
Słowa kluczowe: onkologia przewodu pokarmowegopostępy 2023nowotwór jelita grubegonowotwór przełykunowotwór żołądkanowotwór trzustkinowotwór wątroby
Referencje
- Arnold M, Abnet CC, Neale RE, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020; 159(1): 335–349.e15.
- Wang S, Zheng R, Li J, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. Lancet Gastroenterol Hepatol. 2024; 9(3): 229–237.
- Ben-Aharon I, van Laarhoven HWM, Fontana E, et al. Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications. Cancer Discov. 2023; 13(3): 538–551.
- Koh B, Tan DJ, Ng CH, et al. Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019. JAMA Netw Open. 2023; 6(8): e2328171.
- Conroy T, Etienne PL, Rio E, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2023; 41(17_suppl): LBA3504–LBA3504.
- Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Collaborative Investigators. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023; 278(4): e766–e772.
- Schrag D, Shi Q, Weiser MR, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023; 389(4): 322–334.
- Glynne-Jones R, Wyrwicz L, Tiret E, et al. ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv22–iv40.
- Morton D, Seymour M, Magill L, et al. FOxTROT Collaborative Group. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. J Clin Oncol. 2023; 41(8): 1541–1552.
- Jensen L, Kjaer M, Larsen F, et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clin Oncol. 2023; 41(17_suppl): LBA3503–LBA3503.
- Prager GW, Taieb J, Fakih M, et al. SUNLIGHT Investigators, SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023; 388(18): 1657–1667.
- Cervantes A, Martinelli E. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Ann Oncol. 2024; 35(2): 241–243.
- Dasari A, Lonardi S, Garcia-Carbonero R, et al. FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023; 402(10395): 41–53.
- Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C. N Engl J Med. 2023; 389(23): 2125–2139.
- Shitara K, Rha SY, Wyrwicz LS, et al. KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024; 25(2): 212–224.
- Shitara K, Rha SY, Wyrwicz LS, et al. LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study. Ann Oncol. 2023; 34: S1316.
- Oh DY, Janjigian YY, Al-Batran SE, et al. 129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023; 34: S1520–S1521.
- Terashima M, Kang YK, Kim YW, et al. ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. J Clin Oncol. 2023; 41(16_suppl): 4000–4000.
- Shitara K, Moehler M, Ajani J, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. J Clin Oncol. 2024; 42(3_suppl): 306–306.
- Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10): 1571–1580.
- Rha SY, Oh DY, Yañez P, et al. KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24(11): 1181–1195.
- Janjigian YY, Kawazoe A, Bai Y, et al. KEYNOTE-811 Investigators. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023; 402(10418): 2197–2208.
- Lordick F, Carneiro F, Cascinu S, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(10): 1005–1020.
- Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023; 401(10389): 1655–1668.
- Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023; 29(8): 2133–2141.
- Eyck BM, van Lanschot JJ, Hulshof MC, et al. CROSS Study Group, CROSS study group, CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22): 2074–2084.
- Wilk BJv, Eyck BM, Wijnhoven B, et al. LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial. Ann Oncol. 2023; 34: S1317.
- Nilsson K, Klevebro F, Sunde B, et al. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol. 2023; 34(11): 1015–1024.
- Reynolds JV, Preston SR, O'Neill B, et al. Neo-AEGIS Investigators and Trial Group. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023; 8(11): 1015–1027.
- Kato K, Ajani J, Doki Y, et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. J Clin Oncol. 2023; 41(4_suppl): 290–290.
- Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023; 24(5): 483–495.
- Labori K, Bratlie S, Biörserud C, et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol. 2023; 41(17_suppl): LBA4005–LBA4005.
- Ghaneh P, Palmer D, Cicconi S, et al. European Study Group for Pancreatic Cancer. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023; 8(2): 157–168.
- Koerkamp BG, Janssen QP, Dam JLv, et al. LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial. Ann Oncol. 2023; 34: S1323.
- Conroy T, Pfeiffer P, Vilgrain V, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(11): 987–1002.
- Ohba A, Ozaka M, Ogawa G, et al. 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial. Ann Oncol. 2023; 34: S894.
- Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023; 402(10409): 1272–1281.
- Strickler JH, Satake H, George TJ, et al. Sotorasib in p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023; 388(1): 33–43.
- Nakachi K, Ikeda M, Konishi M, et al. Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401(10372): 195–203.
- Kelley RK, Ueno M, Yoo C, et al. KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10391): 1853–1865.
- Oh DY, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022; 1(8): EVIDoa2200015.
- Shroff R, Guthrie K, Scott A, et al. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2023; 41(4_suppl): LBA490–LBA490.
- Goyal L, Meric-Bernstam F, Hollebecque A, et al. FOENIX-CCA2 Study Investigators. Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med. 2023; 388(3): 228–239.
- Vogel A, Bridgewater J, Edeline J, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(2): 127–140.
- Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023; 402(10415): 1835–1847.
- Li SH, Mei J, Cheng Y, et al. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. J Clin Oncol. 2023; 41(10): 1898–1908.
- Llovet JM, Kudo M, Merle P, et al. LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24(12): 1399–1410.
- Qin S, Chan SL, Gu S, et al. CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023; 402(10408): 1133–1146.
- Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022; 23(8): 995–1008.
- Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023; 9(12): 1651–1659.
